Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novavax Inc 21 Firstfield Road GAITHERSBURG MD 20878 USA

www.novavax.com Employees: 749 P: 240-268-2000

Sector:

Medical

Description:

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.'Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.'Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.'ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

Key Statistics

Overview:

Market Capitalization, $K 1,326,299
Enterprise Value, $K 1,074,789
Shares Outstanding, K 162,936
Float, K 161,307
% Float 99.00%
Short Interest, K 48,625
Short Float 29.84%
Days to Cover 11.29
Short Volume Ratio 0.40
% of Insider Shareholders 1.00%
% of Institutional Shareholders 53.04%

Financials:

Annual Sales, $ 1,123 M
Annual Net Income, $ 440,300 K
Last Quarter Sales, $ 147,140 K
Last Quarter Net Income, $ 17,530 K
EBIT, $ 452,790 K
EBITDA, $ 480,400 K

Growth:

1-Year Return 35.42%
3-Year Return -3.78%
5-Year Return -95.47%
5-Year Revenue Growth 136.22%
5-Year Earnings Growth 144.15%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.11 on 02/26/26
Next Earnings Date 05/14/26
Earnings Per Share ttm 3.04
EPS Growth vs. Prev Qtr 117.74%
EPS Growth vs. Prev Year 121.57%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 05/10/19

NVAX Ratios

Ratio
Price/Earnings ttm 2.66
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -673.17%
Return-on-Assets % 43.53%
Profit Margin % 39.19%
Debt/Equity 0.00
Price/Sales 1.17
Price/Cash Flow 2.31
Price/Book N/A
Book Value/Share -0.79
Interest Coverage 20.61
60-Month Beta 2.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.